Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Camidanlumab Tesirine |
Synonyms | |
Therapy Description |
Camidanlumab Tesirine (ADCT-301) is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Camidanlumab Tesirine | ADCT-301|ADCT 301|ADCT301 | Camidanlumab Tesirine (ADCT-301) is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04639024 | Phase II | Camidanlumab Tesirine | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Recruiting | USA | 0 |
NCT03621982 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | BEL | 1 |
NCT04052997 | Phase II | Camidanlumab Tesirine | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 4 |
NCT02432235 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | Completed | USA | 1 |